Randall J Lee1, Andy Hinson2, Robert Bauernschmitt3, Klaus Matschke4, Qi Fang5, Douglas L Mann6, Robert Dowling7, Nelson Schiller5, Hani N Sabbah8. 1. Cardiovascular Research Institute, University of California-San Francisco, San Francisco, CA, USA; Department of Medicine, University of California-San Francisco, San Francisco, CA, USA; Institute for Regeneration Medicine, University of California-San Francisco, San Francisco, CA, USA. Electronic address: lee@medicine.ucsf.edu. 2. LoneStar Heart, Inc., Laguna Hills, CA, USA. 3. Department for Thoracic and Cardiovascular Surgery, University of Ulm, Ulm, Germany. 4. Cardiovascular Surgery, University Hospital Dresden, Dresden, Germany. 5. Cardiovascular Research Institute, University of California-San Francisco, San Francisco, CA, USA; Department of Medicine, University of California-San Francisco, San Francisco, CA, USA. 6. Cardiovascular Division, Washington University School of Medicine, St Louis, MO, USA. 7. Dowling Consulting, Louisville, KY, USA. 8. Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI, USA.
Abstract
BACKGROUND: A tissue engineering approach to augment the left ventricular wall has been suggested as a means to treat patients with advanced heart failure. This study evaluated the safety and feasibility of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy undergoing open-heart surgery. METHODS AND RESULTS:Eleven male patients (aged 44 to 74years) with advanced heart failure (NYHA class 3 or 4), a left ventricular ejection fraction (LVEF) of <40% and requiring conventional heart surgery received Algisyl-LVR delivered into the LV myocardial free wall. Serial echocardiography, assessment of NYHA class, Kansas City Cardiomyopathy Questionnaire (KCCQ) and 24-hour Holter monitoring were obtained at baseline, days 3 and 8 (for echocardiography and Holter monitoring), and at 3, 6, 12, 18 and 24months. A total of 9 (81.8%) patients completed 24months of follow-up. Two patients withdrew consent after day 8 and at the 3month visit. Operative mortality was 0% (n=10 with 30day follow-up). There were no adverse events attributed to Algisyl-LVR. Mean LVEF improved from 27.1 (±7.3) % at screening to a mean LVEF of 34.8 (±18.6) % 24months post-discharge. Improvements of NYHA class were corroborated with improvements in KCCQ summary scores. Holter monitor data showed a significant decrease in the episodes of nonsustained ventricular tachycardia following administration of Algisyl-LVR. CONCLUSIONS: Administration of Algisyl-LVR to patients with advanced HF at the time of cardiac surgery is feasible and safe; warranting continued development of Algisyl-LVR as a potential therapy in patients with advanced HF.
RCT Entities:
BACKGROUND: A tissue engineering approach to augment the left ventricular wall has been suggested as a means to treat patients with advanced heart failure. This study evaluated the safety and feasibility of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy undergoing open-heart surgery. METHODS AND RESULTS: Eleven male patients (aged 44 to 74years) with advanced heart failure (NYHA class 3 or 4), a left ventricular ejection fraction (LVEF) of <40% and requiring conventional heart surgery received Algisyl-LVR delivered into the LV myocardial free wall. Serial echocardiography, assessment of NYHA class, Kansas City Cardiomyopathy Questionnaire (KCCQ) and 24-hour Holter monitoring were obtained at baseline, days 3 and 8 (for echocardiography and Holter monitoring), and at 3, 6, 12, 18 and 24months. A total of 9 (81.8%) patients completed 24months of follow-up. Two patients withdrew consent after day 8 and at the 3month visit. Operative mortality was 0% (n=10 with 30day follow-up). There were no adverse events attributed to Algisyl-LVR. Mean LVEF improved from 27.1 (±7.3) % at screening to a mean LVEF of 34.8 (±18.6) % 24months post-discharge. Improvements of NYHA class were corroborated with improvements in KCCQ summary scores. Holter monitor data showed a significant decrease in the episodes of nonsustained ventricular tachycardia following administration of Algisyl-LVR. CONCLUSIONS: Administration of Algisyl-LVR to patients with advanced HF at the time of cardiac surgery is feasible and safe; warranting continued development of Algisyl-LVR as a potential therapy in patients with advanced HF.
Authors: Jun Fang; Jaekyung Koh; Qizhi Fang; Huiliang Qiu; Maani M Archang; Mohammad Mahdi Hasani-Sadrabadi; Hiromi Miwa; Xintong Zhong; Richard Sievers; Dong-Wei Gao; Randall Lee; Dino Di Carlo; Song Li Journal: Adv Funct Mater Date: 2020-09-06 Impact factor: 18.808
Authors: Yuri M Klyachkin; Amr Idris; Christopher B Rodell; Himi Tripathi; Shaojing Ye; Prabha Nagareddy; Ahmed Asfour; Erhe Gao; Rahul Annabathula; Mariusz Ratajczak; Jason A Burdick; Ahmed Abdel-Latif Journal: Stem Cell Rev Rep Date: 2018-10 Impact factor: 5.739
Authors: Kevin L Sack; Eric Aliotta; Jenny S Choy; Daniel B Ennis; Neil H Davies; Thomas Franz; Ghassan S Kassab; Julius M Guccione Journal: Acta Biomater Date: 2020-05-16 Impact factor: 8.947
Authors: C T Moody; A E Brown; N P Massaro; A S Patel; P A Agarwalla; A M Simpson; A C Brown; H Zheng; J G Pierce; Y Brudno Journal: Acta Biomater Date: 2021-10-30 Impact factor: 8.947